113 related articles for article (PubMed ID: 342393)
21. Induction of high-grade tumor-specific immunity in a host using a cytotoxic T-lymphocyte clone specific for a stable tumor antigen on murine leukemia L1210.
Rahman SM; Kawashima K; Nakashima I; Nagase F
Cancer Res; 1988 Nov; 48(22):6450-4. PubMed ID: 3263189
[TBL] [Abstract][Full Text] [Related]
22. Monoclonal antibody-recognizing tumor-associated antigen of DBA/2 mouse lymphoma L1210 and its sublines.
Fuji H
Transplant Proc; 1980 Sep; 12(3):388-90. PubMed ID: 6784299
[TBL] [Abstract][Full Text] [Related]
23. Expression of alien H-2 specificities of a chemically induced BALB/c fibrosarcoma.
Meschini A; Invernizzi G; Parmiami G
Int J Cancer; 1977 Aug; 20(2):271-83. PubMed ID: 70414
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxicity of vivo sensitized lymphocytes on allogeneic third-party fibroblasts differing for various regions of the H-2 complex.
Jorgensen PN; Florentz K; Güttler F
Transplant Proc; 1974 Mar; 6(1):95-9. PubMed ID: 4817057
[No Abstract] [Full Text] [Related]
25. Transplantation of CD95 ligand-expressing grafts: influence of transplantation site and difficulty in protecting allo- and xenografts.
Seino K; Kayagaki N; Tsukada N; Fukao K; Yagita H; Okumura K
Transplantation; 1997 Oct; 64(7):1050-4. PubMed ID: 9381528
[TBL] [Abstract][Full Text] [Related]
26. Fetal liver cell transplantation in various murine models.
Sanhadji K; Touraine JL; Aitouche A; Vicari A; Chargui J; Goillot E
Bone Marrow Transplant; 1992; 9 Suppl 1():77-82. PubMed ID: 1504674
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of natural killer cell-mediated bone marrow graft rejection by allogeneic major histocompatibility complex class I, but not class II molecules.
Ohlén C; Höglund P; Sentman CL; Carbone E; Ljunggren HG; Koller B; Kärre K
Eur J Immunol; 1995 May; 25(5):1286-91. PubMed ID: 7774631
[TBL] [Abstract][Full Text] [Related]
28. Augmentation of syngeneic tumor-specific immunity by semiallogeneic cell hybrids.
Toffaletti DL; Darrow TL; Scott DW
J Immunol; 1983 Jun; 130(6):2982-6. PubMed ID: 6189910
[TBL] [Abstract][Full Text] [Related]
29. Alien H-2 allospecificities in murine chemically-induced tumors.
Merino F
Immunol Commun; 1979; 8(5-6):555-62. PubMed ID: 94037
[TBL] [Abstract][Full Text] [Related]
30. Studies of H-2 restriction in cell-mediated cytotoxicity and transplantation immunity to Leukemia-associated antigens.
Ting CC; Law LW
J Immunol; 1977 Apr; 118(4):1259-64. PubMed ID: 191534
[TBL] [Abstract][Full Text] [Related]
31. Multiple foreign non-H-2 determinants on the surface of a chemically-induced murine sarcoma.
Invernizzi G; Carbone G; Meschini A; Parmiani G
J Immunogenet; 1977 Apr; 4(2):97-106. PubMed ID: 874338
[TBL] [Abstract][Full Text] [Related]
32. Antigenic changes associated with resistance to methotrexate and 6-mercaptopurine in L1210 ascites lymphoma.
Calman NS; Eng B; Slater LM; Wallerstein H
J Natl Cancer Inst; 1974 Mar; 52(3):997-8. PubMed ID: 4826575
[No Abstract] [Full Text] [Related]
33. [Antitumor resistance induced by immunization with normal definitive tissues].
Bodrova BL
Tsitologiia; 1979 Nov; 21(11):1342-7. PubMed ID: 93333
[TBL] [Abstract][Full Text] [Related]
34. Facilitating cells enable engraftment of purified fetal liver stem cells in allogeneic recipients.
Gaines BA; Colson YL; Kaufman CL; Ildstad S
Exp Hematol; 1996 Jul; 24(8):902-13. PubMed ID: 8690049
[TBL] [Abstract][Full Text] [Related]
35. Fate of H2-activated T lymphocytes in syngeneic hosts. II. Residence in recirculating lymphocyte pool and capacity to migrate to allografts.
Sprent J; Miller JF
Cell Immunol; 1976 Feb; 21(2):303-13. PubMed ID: 769995
[No Abstract] [Full Text] [Related]
36. Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts.
Zeis M; Uharek L; Glass B; Gaska T; Gassmann W; Mueller-Ruchholtz W
Bone Marrow Transplant; 1994 Nov; 14(5):711-5. PubMed ID: 7889004
[TBL] [Abstract][Full Text] [Related]
37. Tumour-associated transplantation antigens of chemically induced sarcomata cross reacting with allogeneic histocompatibility antigens.
Invernizzi G; Parmiani G
Nature; 1975 Apr; 254(5502):713-4. PubMed ID: 1091865
[No Abstract] [Full Text] [Related]
38. Cytotoxic T lymphocytes to murine plasmacytoma cells in allogeneic and syngeneic mice: H-2 antigens are essential in the induction and effector stages of CTL.
Kaneko Y; Natsuume-Sakai S; Migita S
J Immunol; 1978 Aug; 121(2):427-37. PubMed ID: 79604
[No Abstract] [Full Text] [Related]
39. Differing contribution of various effector cells in the elimination of syngeneic or allogeneic cells.
Matsumoto T; Himeno K; Mitani M; Mori K; Miake S; Nomoto K
J Clin Lab Immunol; 1986 Feb; 19(2):83-9. PubMed ID: 3083105
[TBL] [Abstract][Full Text] [Related]
40. Novel tumor-specific antigen(s) response observed in a syngeneic lymphoma-bearing host.
Manson LA
Cancer Detect Prev Suppl; 1987; 1():111-20. PubMed ID: 3121177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
